These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28412368)

  • 1. HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells.
    Liu J; Sun W; Dong W; Wang Z; Qin Y; Zhang T; Zhang H
    Biochem Biophys Res Commun; 2017 May; 487(2):313-319. PubMed ID: 28412368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.
    Walsby E; Pearce L; Burnett AK; Fegan C; Pepper C
    Oncotarget; 2012 May; 3(5):525-34. PubMed ID: 22619113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
    Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
    Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
    Garon EB; Finn RS; Hamidi H; Dering J; Pitts S; Kamranpour N; Desai AJ; Hosmer W; Ide S; Avsar E; Jensen MR; Quadt C; Liu M; Dubinett SM; Slamon DJ
    Mol Cancer Ther; 2013 Jun; 12(6):890-900. PubMed ID: 23493311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Tumour Biol; 2017 Oct; 39(10):1010428317722068. PubMed ID: 28982310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
    Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
    Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of heat shock protein 90 with AUY922 represses tumor growth in a transgenic mouse model of islet cell neoplasms.
    Fendrich V; Wichmann S; Wiese D; Waldmann J; Lauth M; Rexin P; L-Lopez C; Schlitt HJ; Bartsch DK; Lang SA
    Neuroendocrinology; 2014; 100(4):300-9. PubMed ID: 25301256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat Shock Protein 90 Inhibitors AUY922, BIIB021 and SNX5422 Induce Bim-mediated Death of Thyroid Carcinoma Cells.
    Kim SH; Cho YK; Huh JH; Kang JG; Ihm SH; Choi MG; Lee SJ
    Anticancer Res; 2020 Nov; 40(11):6137-6150. PubMed ID: 33109551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.
    Taniguchi H; Hasegawa H; Sasaki D; Ando K; Sawayama Y; Imanishi D; Taguchi J; Imaizumi Y; Hata T; Tsukasaki K; Uno N; Morinaga Y; Yanagihara K; Miyazaki Y
    Cancer Sci; 2014 Dec; 105(12):1601-8. PubMed ID: 25263741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
    Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.
    Su YH; Tang WC; Cheng YW; Sia P; Huang CC; Lee YC; Jiang HY; Wu MH; Lai IL; Lee JW; Lee KH
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2261-72. PubMed ID: 25982393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma.
    Okui T; Shimo T; Hassan NM; Fukazawa T; Kurio N; Takaoka M; Naomoto Y; Sasaki A
    Anticancer Res; 2011 Apr; 31(4):1197-204. PubMed ID: 21508365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer.
    Yeramian A; García V; Bergadà L; Domingo M; Santacana M; Valls J; Martinez-Alonso M; Carceller JA; Cussac AL; Dolcet X; Matias-Guiu X
    Mol Imaging Biol; 2016 Aug; 18(4):545-56. PubMed ID: 26604096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.
    Eccles SA; Massey A; Raynaud FI; Sharp SY; Box G; Valenti M; Patterson L; de Haven Brandon A; Gowan S; Boxall F; Aherne W; Rowlands M; Hayes A; Martins V; Urban F; Boxall K; Prodromou C; Pearl L; James K; Matthews TP; Cheung KM; Kalusa A; Jones K; McDonald E; Barril X; Brough PA; Cansfield JE; Dymock B; Drysdale MJ; Finch H; Howes R; Hubbard RE; Surgenor A; Webb P; Wood M; Wright L; Workman P
    Cancer Res; 2008 Apr; 68(8):2850-60. PubMed ID: 18413753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
    Bao XH; Takaoka M; Hao HF; Fukazawa T; Yamatsuji T; Sakurama K; Takigawa N; Nakajima M; Fujiwara T; Naomoto Y
    Oncol Rep; 2013 Jan; 29(1):45-50. PubMed ID: 23064324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922.
    Kühnel A; Schilling D; Combs SE; Haller B; Schwab M; Multhoff G
    Cells; 2019 Sep; 8(10):. PubMed ID: 31569342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.